# A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread

> **NCT03166631** · PHASE1 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 62 (actual)

## Conditions studied

- Neoplasms
- Neoplasm Metastasis
- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** BI 891065
- **DRUG:** BI 754091

## Key facts

- **NCT ID:** NCT03166631
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-08
- **Primary completion:** 2020-09-15
- **Final completion:** 2020-10-28
- **Target enrollment:** 62 (ACTUAL)
- **Why stopped:** Not due to safety reasons.
- **Last updated:** 2024-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03166631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03166631, "A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03166631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*